组织学特征对浸润性导管内乳头状黏液癌辅助化疗的影响。

Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma.

机构信息

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Department of Pathology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

出版信息

Anticancer Res. 2022 May;42(5):2645-2655. doi: 10.21873/anticanres.15742.

DOI:10.21873/anticanres.15742

PMID:35489761

Abstract

BACKGROUND/AIM: This study evaluated the efficacy of adjuvant chemotherapy (AC) for intraductal papillary mucinous carcinoma (IPMC).

PATIENTS AND METHODS

We retrospectively analyzed patients who underwent pancreatectomy for invasive IPMC from January 2007 to June 2020. We evaluated outcomes of AC in the entire cohort and in patients with known prognostic factors.

RESULTS

A total of 51 patients with invasive IPMC underwent surgery, of which 35 received AC. In the entire cohort, there was no significant difference in median overall survival (OS) between the AC and surgery alone (SA) group [hazard ratio (HR)=0.54; p=0.232]. For patients with poorly differentiated adenocarcinoma, median OS was significantly longer in the AC group (HR=0.27; p=0.022). For patients with lymph node metastasis, median OS was significantly higher in the AC group (HR=0.07; p<0.001).

CONCLUSION

AC may be effective for selected invasive IPMC patients.

摘要

背景/目的：本研究评估了辅助化疗（AC）对导管内乳头状黏液性癌（IPMC）的疗效。

患者与方法

我们回顾性分析了 2007 年 1 月至 2020 年 6 月期间因浸润性 IPMC 行胰腺切除术的患者。我们评估了 AC 在整个队列和已知预后因素患者中的疗效。

结果

共有 51 例浸润性 IPMC 患者接受了手术，其中 35 例接受了 AC。在整个队列中，AC 组与单纯手术（SA）组的中位总生存期（OS）无显著差异[风险比（HR）=0.54；p=0.232]。对于分化差的腺癌患者，AC 组的中位 OS 明显更长（HR=0.27；p=0.022）。对于有淋巴结转移的患者，AC 组的中位 OS 明显更高（HR=0.07；p<0.001）。